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INTRODUCTION
Crohn’s disease (CD) is an inflammatory bowel disease for which several medical
therapies are currently available. Despite the significant untoward side effects of systemic
corticosteroids, these drugs are typically initiated before a trial of a more gut‐specific biologic
treatment such as a recombinant humanized monoclonal antibody or anti‐tumor necrosis factor
(TNF) antibody. Because there are currently no evidence‐based guidelines for the treatment
moderate‐to‐severe (MTS) CD, expert opinion largely forms the guidelines by which we initiate
corticosteroids and then follow with trials of biologics. Current conventional guidelines follow a
‘step care’ or ‘step ladder’ plan which is an incremental approach in which corticosteroids and
immunosuppressants are started sequentially. However, this approach does not prevent
disease progression and demonstrates an important risk of adverse events from repeated
courses of corticosteroids.1
Crohn’s Disease consists of phases of relapse and remission. A clinician’s objective is to
induce and maintain remission of CD, which is currently defined as complete mucosal healing
identified via endoscopic evaluation, and normalization of serological activity indexes, including
c‐reactive protein and erythrocyte sedimentation rate.2 The course and severity of CD, often
measured using the Crohn’s disease activity index (CDAI),3,4 differs from one patient to another.
The CDAI is widely used to asses severity, medication efficacy and remission in patients with CD.
Scores can range from zero to over 600 and are based on patient reported information, using a
seven‐day diary, as well as other measurements including a patient’s weight and hematocrit. If
a patient has a score of greater than 220 it is defined as moderate to severe disease with a
score of greater than 300 representing severe disease. Remission is reached when a patient has
a CDAI score of less than 150. Many research studies are classifying medication response as a
reduction in the CDAI of greater than 70 points. However, this could be confusing if clinicians
are trying to establish guidelines which include complete mucosal healing, which is not noted
on the CDAI. It also does not account for medications tried or failed, therefore a patient’s CDAI
score may not calculate into the proper category when in fact they have corticosteroid‐
refractory, moderate‐to‐severe CD.5 Therefore, a clearer guideline is needed for patients with
corticosteroid‐refractory moderate‐to‐severe CD.
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Population‐based data from 1935‐2008 shows that only 10% of patients with CD will
have prolonged clinical remission. Of all patients diagnosed with CD, 50% of patients will have
an intestinal complication within 20 years after diagnosis. It is estimated that about 20% of CD
patients will be admitted to the hospital at least annually and 50% of the patients will require
intestinal surgery 10 years after diagnosis. 6
There are many medications indicated for the treatment of CD. Selection should aim to
balance side‐effects and long‐term complications. The initial choice in medication treatment
should also incorporate the individual profile of the patient as well making more potent
medications available to higher risk patients instead of the standard stepwise approach.6 While
the immunosuppressive medications azathioprine, 6‐mercaptopurine and methotrexate are
corticosteroid‐sparing, they are not highly effective at mucosal healing or disease prevention.
Because of this factor, immunosuppressive medications were not directly compared in this
review.1

THE USE OF CORTICOSTEROIDS IN CROHN'S DISEASE
Corticosteroid therapy has been a gold‐standard medication in the treatment of CD for
acute attacks and is often the initial treatment for newly diagnosed patients. Current guidelines
recommend that patients with active disease be treated with corticosteroid therapy. The
recommendation is currently written as corticosteroids for first line therapy with treatment
time limited at 3‐4 months as patients could start experiencing toxic effects at treatments
greater than 6 months.7 However, steroid use is associated with injurious systemic effects, bone
loss, and medication interactions, and patients become dependent on these medications to
keep their disease controlled.
A recent study by T. Molnar et al. revealed that initiating steroids as the first line of
treatment causes faster relapse in some patients. One group of MTS CD patients who initiated
steroids at the time of diagnosis, and subsequently started on a biologic, only achieved
remission for one year or less. Other patients who were not started on steroids prior to
initiation of biologics stayed in remission longer.3 Therefore, corticosteroids are effective at
initiating, but not maintaining, a state of remission. Moreover, many patients who respond to
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corticosteroids become dependent on therapy and therefore cannot be weaned off, resulting in
a true failure of clinical remission.8
Extended exposure to corticosteroid treatment is also associated with the complications
of Cushing’s syndrome and therefore an increased risk of mortality. Some practitioners have
chosen to forgo the use of corticosteroids altogether, to reduce the risk of the aforementioned
risks, and use instead corticosteroid‐sparing drugs such as azathioprine, mercaptopurine or
methotrexate. The issue with these immunosuppressive drugs is that they are not
recommended to be started in the earlier course of the disease. This is why it is so important to
bring biologics to the forefront of the battle against CD.7

INFLIXIMAB
Infliximab (Remicade), a tumor necrosis factor alpha (TNF‐α), is a proinflammatory
cytokine that has an important role in the pathogenesis of inflammatory bowel disease, and
more specifically CD.4 Infliximab is a chimeric anti‐TNFα monoclonal antibody which binds to
TNFα with high affinity, thereby neutralizing its biological activity.4 Current guidelines, as noted
above, recommend concomitant use of a thiopurine analog with scheduled Infliximab (IFX) for
the induction and maintenance of remission in MTS CD.10 This approach to therapy was
adapted from the treatment of Rheumatoid arthritis (RA) for patients at high risk of disease
progression. It uses the ‘top‐down’ approach using methotrexate with a TNF antagonist. The
concept driving this combination is the recognition that combined therapy is more effective
than monotherapy.1
Neutralization of TNF has been shown to decrease recruitment of inflammatory cells
and granuloma formation in several animal models. One study’s aim was to investigate the
safety and potential efficacy of an anti‐TNF monoclonal antibody in the treatment of active CD
in patients with steroid‐refractory disease.9 The study consisted on ten patients with an age
range of 20‐64 years and each patient was considered to have active CD based on CDAI with a
mean score of 258; representing moderate to severe disease. Treatment consisted of a single
intravenous infusion of the anti TNF at a dose of 10 mg/kg and two patients were selected to
receive 20 mg/kg to evaluate the safety at a higher dose. Drug therapies were continued for a
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two months span which included the whole study period. Videoendoscopy of the colon was
performed one day before the infusion and at weeks four and eight. One patient was excluded
from the study because the CDAI could not be verified. Nine patients remained in the study and
of those nine, eight reported improvement in subjective symptoms within one week after
treatment. Four weeks after infusion these same eight patients scored “excellent or good
response to treatment” on the subjective scoring list. At the beginning of the study the mean
CDAI study was 257 before treatment and decreased to 114 at two weeks into the study, 79 at
four weeks, 61 at six weeks and 69 at week eight. The study provides evidence that TNF‐ is a
major factor in the pathophysiology of CD.9 This study was not designed to show the long‐term
efficacy of anti‐TNF nor did it look at maintenance of remission; this study was small and
uncontrolled and therefore, longer controlled, trials will need to be performed.
Some patients with MTS active CD will not have a response to TNF antagonists available,
and the trial of a second TNF antagonist decreases the efficacy of the second drug compared to
a patient who has never received a TNF antagonist. This is where veldolizumab comes into the
picture.13

VEDOLIZUMAB
Vedolizumab (Entyvio) is a humanized α4β7 integrin, immunoglobulin G1 monoclonal
antibody. Its selective inhibition allows for inhibition of the α4β7/MAdCAM‐1 pathway and
should ameliorate gastrointestinal inflammation without inhibiting systemic immune responses
or affecting T‐cell trafficking to the CNS. A randomized, placebo‐controlled, double‐blind,
multinational, multicenter trial named the GEMINI looked to determine the effects of
vedolizumab induction therapy on clinical remission. The third phase of this trial, initiated in
November 2010 and completed in April 2012, showed an increase in remission rates from
weeks six to ten in the overall study population while sparing these patients of the effects of
corticosteroids. These findings support the safety of vedolizumab in patients with CD and are
consistent with the drug’s postulated gut‐selective mechanism of action.12
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COST AND BENEFIT
Prior to the emergence of biologic medical therapy, MTS CD patients suffered increased
hospitalization rates; furthermore, 40‐50% of patients required surgery within 10 years from
the time of diagnosis. More recently, data from Kaiser Permanente in Canada and Northern
California reveal that biologic medical therapy has helped decrease hospitalizations rates in
patients with MTS CD. In addition, a Manitoba Canada study reported reduced surgery rates in
the post‐biologic induction period and a decreased postoperative recurrence about 50% after
10 years.11 Despite these advances, many patients cannot afford the high cost of these new
medications. A recent technical review by the American Gastroenterological Association
Institute reported annual treatment costs of $8265 per patient, extrapolating to yearly costs of
$2.5 to $4 billion for the American population with CD.13

RECOMMENDATIONS
The official recommendations of the American Gastroenterological Association Institute
(AGA) include using Anti‐TNF‐α Drugs to induce remission in patients with MTS CD, reporting
with strong recommendation and Moderate‐Quality Evidence grade. Evidence shows that the
anti‐TNF‐α drugs infliximab or adalimumab are more likely than the placebo to induce
remission in patients with MTS CD refractory to other therapies including corticosteroids.13
However, there is no recommendation for the use of biologics alone to maintain clinical
remission in patients with MTS CD.
One main issue with current guidelines for MTS CD is that they focus on managing acute
flares and then managing the maintenance of clinical remission, instead of clinical remission
being the primary focus. Use of corticosteroids remains first‐line therapy for acute flare‐ups and
then reserving immunosuppressive agents for patients who develop corticosteroid
dependency.1 There is no real guideline or recommendation as to when a TNF‐ or humanized
α4β7 integrin, immunoglobulin G1 monoclonal antibody can be initiated in patients with MTS
CD in the presence of early disease and to maintain remission.
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SUMMARY
As it stands today, corticosteroids are initiated for an acute attack or a new diagnosis for
a patient with CD. Biologics such as Entyvio or Remicade are started later, with the hope of
steroid‐free disease remission. Studies have shown that clinical deep remission without steroid
use is possible using biologics, and these drugs can be used as maintenance therapy as well.
Often, the most common treatment regimen for patients with corticosteroid‐refractory MTS CD
involves choosing a thiopurine, an anti TNF‐ monoclonal antibody, or both.10 Many clinical trials
have been completed to assess efficacy which was published in a review article by Côté‐
Daigneault et al. and is laid out in the table below.17

Cheifetz AS, Feuerstein JD. Treatment of inflammatory bowel disease with biologics. 1st ed. 2018 ed. Cham: Springer Verlag; 2018:420428. https://ebookcentral.proquest.com/lib/[SITE_ID]/detail.action?docID=5143365. 10.1007/978-3-319-60276-9

Unfortunately, only a limited number of trials have been performed to demonstrate the
effectiveness of the recombinant humanized monoclonal antibody Vedolizumab, and the anti‐
TNF antibody Infliximab in induction/maintenance of remission of corticosteroid‐refractory
moderate‐to‐severe inflammatory bowel disease. More extensive research will help to change
treatment guidelines as a whole and will help to determine the exact patient population who
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would benefit from starting a biologic as the first line of treatment. This will also help to
determine if corticosteroids should be initiated at all, especially since the goal is complete
mucosal healing and clinical remission free of corticosteroid therapy.
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